The Triad

a) Clinical Trial on VF001
b) Partnering
c) Cash

This triad will decide FTT future.

a) Clinical trial is running. Strategic capital has been already put in place by a limited number of funds. The mass is still sleeping and afraid to invest. Previous clinical trial results in Europe had been very promising. The outcome should be positive, otherwise no reason to write and speak.

b) Partnering is a critical factor. No ifs and independent actions. Previous mismanagement missing in this strategy had caused a list of post-failures. The most critical failure was the mismanagement of previous clinical trial and data collection. The partner will be the fulcrum of any future FTT policies.

c) No cash no life. We need the cash to avoid a disruptive capital raising and keep the company following its objectives. Positive clinical trial should lead to partnering and cash. The ways in which a partnering player can play this financing game could lead to an independent company leader on its sector, or a potential buy out and a further de-listing.
Hard to think that a US company buying the patents would keep FTT alive. In general, the technology is absorbed into their existing platform, unless R&D is so strong that is better to keep the company alive due to its location and partners list. (Universities, know-how and so on)